| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $121.6M | +117.5% |
| SG&A Expense | $26.2M | +33.5% |
| Operating Income | -$147.8M | -95.7% |
| Net Income | -$140.2M | -94.0% |
| EPS (Basic) | -$2.39 | -27.8% |
| EPS (Diluted) | -$2.39 | -27.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $139.9M | -36.3% |
| Current Assets | $265.0M | +19.0% |
| Total Assets | $300.8M | +29.6% |
| Current Liabilities | $26.8M | +57.2% |
| Total Liabilities | $45.1M | +151.7% |
| Stockholders' Equity | $255.7M | +19.4% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$118.6M | -101.9% |
| Capital Expenditures | $6.9M | +299.2% |
| Investing Cash Flow | -$124.7M | -7155.3% |
| Financing Cash Flow | $163.6M | +330.7% |
| Free Cash Flow | -$125.5M | -107.5% |